1. Introduction {#sec1}
===============

Type I interferon (IFN) cytokines are the first-line of defense against viral infections. They act through the immune system by rapidly inducting cellular modulators, thus inhibiting viral replication and spreading ([@bib4]). Viral infections yield highly conserved pathogen-associated molecular patterns (PAMPs), such as double-stranded RNA (dsRNA). Viral RNA contains short hairpin dsRNA with triphosphorylated 5′ end (5′pppRNA) that preferentially activates host\'s pattern recognition receptors (PRRs), including the retinoic acid inducible gene-I (RIG-I) receptor ([@bib29]). Tripartite motif (TRIM) proteins, TRIM25 ([@bib15]) and TRIM4 ([@bib49]), play a critical role in RIG-I activation through K63-linked ubiquitination. The activated RIG-I further interacts with mitochondrial antiviral-signaling protein (MAVS) and stimulates transcription factor, IFN regulatory factor-3/7 (IRF-3/7) to induce IFN gene expression ([@bib45]). IFNs, secreted from virus-infected cells, bind to the IFN receptor (IFNAR) on the cell surface to initiate the JAK-STAT pathway. This upregulates hundreds of IFN-stimulated gene products (ISGs) and suppresses viral infection ([@bib6], [@bib35]). RIG-I agonists have been shown to induce IFN\'s expression and multiple innate antiviral response to control a number of viral infections. These include, vesicular stomatitis virus (VSV) of the family *Rhabdoviridae* ([@bib17]), hepatitis C virus (HCV) of the family *Flaviviridae* ([@bib17]), influenza virus of the family *Orthomyxoviridae* ([@bib8]), and herpes simplex virus type 1 (HSV-1) of the family *Herpesviridae* ([@bib26]).

Viral infections, including rhabdovirus ([@bib27]), paramyxovirus ([@bib25]), orthomyxovirus ([@bib39]), coronavirus ([@bib47]), and herpesvirus ([@bib46]), may counteract RIG-I-dependent IFN antiviral response. It has also been reported that viruses utilize the host cell\'s deubiqutinases and ubiquitin ligases to antagonize RIG-I-mediated innate immune response and succeed in viral replication. Cellular ubiquitin-specific proteases, USP21 ([@bib14]), USP3 ([@bib10]) and USP15 ([@bib56]), a subfamily of deubiqutinase ([@bib32]), remove K63-linked polyubiquitin chains from RIG-I and block it to induce IFN-β. Moreover, a cellular protein antagonizes the activation of RIG-I and participates in the innate immune response during viral infection. Such as Syndecan-4 (SDC4) and NOD-like receptor family CARD domain containing 5 (NLRC5) protein can interact with RIG-I to negatively regulate type I IFN antiviral response ([@bib9], [@bib24]). The level of antiviral cytokines is significantly higher in USP21/SDC4- deficient mice. It should be noted that USP21/SDC4- deficient mice are more resistant to viral infection as compared with the control mice ([@bib14], [@bib24]). It can thus be inferred that the depression of endogenous negative regulators of type I IFN exhibits a potential antiviral effect.

Glioma tumor suppressor candidate region gene 2 protein (GLTSCR2) is a nucleolar protein that contains multiple nucleolar localization sequences ([@bib21]). GLTSCR2 physically interacts with phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and modulates programmed cell death ([@bib30], [@bib51]). Our previous study showed that viral infection induces translocation of GLTSCR2 from the nucleus to the cytoplasm. Cytoplasmic GLTSCR2 blocks IFN-β induction and deactivates RIG-I by negatively regulating it via K63-linked ubiquitination ([@bib43]). In present study, we find that purified G4-T, which mimics GLTSCR2 protein, promotes efficient proliferation of DNA and RNA viruses of distinct genera. We also develop a short hairpin RNA (shRNA) plasmid that targets a specific GLTSCR2 gene. Treatment of GLTSCR2-specific shRNA is found to significantly inhibit *in vitro* and *in vivo* infections. This paper provides solid evidence that GLTSCR2 is a valuable target for developing cell-based antivirals.

2. Materials and methods {#sec2}
========================

2.1. Cells {#sec2.1}
----------

HEp-2, HeLa, Vero, HEK293T, MDCK, and chicken embryo fibroblast DF-1 cells are cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 2 mM L-glutamine, nonessential amino acids, sodium pyruvate, 5% or 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin (all reagents are purchased from Gibco Invitrogen). Human hepatocellular liver carcinoma cell lines Huh7.5.1 are provided by Dr. Francis Chisari at Scripps Research Institute, Florida, USA. All cells are cultured at 37 °C in a humidified incubator with 5% CO~2~.

2.2. Viruses {#sec2.2}
------------

Enterovirus A71 (EV-A71) strain BC08 ([@bib41]), avian influenza virus (AIV) strain H9-WD ([@bib44]), canine distemper virus (CDV) strain MD77 ([@bib22]), Newcastle disease virus (NDV) strain Lasota and infectious bronchitis virus (IBV) strain M41 ([@bib23]), porcine epidemic diarrhea virus (PEDV) strain CV777 ([@bib37]), VSV strain Indiana ([@bib43]), HSV-1 strain F ([@bib40]) and HCV strain JFH-1 ([@bib48]) are reproduced in RD, MDCK, Vero, HeLa, Vero, HeLa, HEK293T, HeLa and Huh7.5.1 cells respectively, according to the reports indicated above. GFP-NDV strain NA-1 is generated by inserting an additional transcription cassette coding for the enhanced GFP between the P and M genes of the NDV genome ([@bib42]). The HCV genotype 1b replicon-containing cell line (2−3+) is provided by Dr. Stanley Lemon at University of Texas Medical Branch, USA ([@bib50]).

2.3. Antibodies {#sec2.3}
---------------

Rabbit polyclonal antibody to GLTSCR2 (used at 1:1000) is acquired from abcam. The anti NDV-P (1:1000), CDV-N (1:1000), VSV-G (1:200) mouse monoclonal antibodies are obtained from Santa Cruz. The antibodies to actin (1:1000) and His (1:1000) are obtained from Beyotime Biotechnology. The antibody to HCV-core (1:400) is preserved in our laboratory. Antibodies are diluted in PBS containing 5% skim milk (pH 7.3).

2.4. Protein production and purification {#sec2.4}
----------------------------------------

G4-T, in which HIV-derived cell-penetrating Tat peptide ([@bib31], [@bib33]) is conjugated at the C-terminal of G4, is constructed and cloned into the expression vector pET-28a *Nde*I-*EcoR*I restriction sites. *Escherichia coli* strain BL21(DE3) transformed with the recombinant His-tagged G4-T plasmid is grown at 37 °C in LB to an optical density of 0.8 (OD at 590 nm) before being induced with 1 mM IPTG for 4 h. Bacterial cells are harvested in PBS (pH 7.3) by centrifugation at 6000*g* for 20 min at 4 °C. The pellet is resuspended in 10 vol of pellet of lysis buffer (20 mM Tris-HCl, 100 mM NaCl, pH 8.0) in the presence of the protease inhibitor cocktail (Roche). After sonication, the cell suspension is fractionated by centrifugation at 6000g for 20 min at 4 °C. Supernatants (soluble fractions) are passed over to nickel-nitrilotriacetic acid (Ni-NTA) columns. Following the binding to column, the column is washed with lysis buffer containing increasing concentrations of imidazole (10, 20, 50, and 200 mM). His-fused protein G4-T is eluted and concentrated by ultrafiltration of 5 K membranes (Millipore), and stored at −80 °C.

2.5. Gel-filtration analysis {#sec2.5}
----------------------------

The purified G4-T protein eluted from His-Ni column is loaded onto the Superdex G200 column in a solution buffer of 20 mM Tris-HCl, pH 8.0. The analytical column is calibrated with a series of individual runs of standard molecular mass proteins as markers, including bovine serum albumin (68 kDa), egg white albumin (43 kDa), and ribose nucleotidase (13.7 kDa). The peak protein is collected and analyzed on 10% SDS-PAGE.

2.6. Chemical cross-linking {#sec2.6}
---------------------------

Purified protein G4-T is incubated at 4 °C in the presence of 0.05% Glutaraldehyde (GA, MP Biomedicals) for 15 min. The reaction is terminated by the addition of 200 mM Tris-HCl buffer, pH 8.0. Cross-linking products are analyzed by 10% SDS-PAGE and Western blotting.

2.7. Circular dichroism (CD) spectra analysis {#sec2.7}
---------------------------------------------

The highly purified G4-T by the gel-filtration is incubated at the final concentration of 30 μM in PBS, with 0%, 25%, or 50% 2,2,2-trifluoroethanol (TFE). The wavelength-dependence of molar ellipticity \[θ\] is monitored at 25 °C as the average of eight scans in a spectropolarimeter (Model J-710, JASCO), equipped with a thermoelectric temperature controller. The thermal denaturation temperature (Tm) is measured at 222 nm by recording the CD signal in the temperature range of 20--75 °C with a scan rate of 1 °C/min.

2.8. Quantitative real-time PCR (RT-PCR) {#sec2.8}
----------------------------------------

Replicate cultures are harvested and total RNA is extracted with Trizol (Invitrogen). A two-step RT-PCR (SYBR Green I technology, Applied Roche) is performed using SYBR green supermix (Toyobo) according to the manufacturer\'s protocol to measure transcription levels for several genes of interest. The primers used are as follows. IFN-β: 5′- CCT ACA AAG AAG CAG CAA-3′ (forward), 5′- TCC TCA GGG ATG TCA AAG -3′ (reverse). PKR: 5′- TAC GCC TGA CCA CAA CTA -3′ (forward), 5′- GGT ATT CCT TCC CGT CTA -3′ (reverse). ISG56: 5′- CAC CCA CTT CTG TCT TACT -3′ (forward), 5′- ACA TTC TTG CCA GGT CTA -3′ (reverse). NDV-N: 5′- TGA TGA CCC AGA AGA TAG ATG GAG -3′ (forward), 5′- CTG TGA GTG GGA GCA TAA AAG AGA -3′ (reverse). ICP8: 5′- GAC GGG CAA TCA GCG GTT CGC -3′ (forward), 5′- TCG TCC AGG TCG TCG TCA TCC -3′ (reverse). HCV-NS5A: 5′- TAG GTG CTG GGT CCA AATC -3′ (forward), 5′- TAT GCT GGC GAG GCT TAT -3′ (reverse). IBV-N: 5′- GGT TGC TGCT AAG GGT GC-3′ (forward), 5′- GCC TTT GTA ATG CGG GAG-3′ (reverse). GAPDH: 5′- CTG GTG ACC CGT GCT GCT T-3′ (forward), 5′- TTG CCG CCT TCT GCC TTA-3′ (reverse). Relative fold changes are automatically calculated by the Step One Plus real-time PCR system software (Applied Biosystems), following the ΔΔC~T~ method. GAPDH is also determined and used as internal control.

2.9. LDH assay for toxicity analysis {#sec2.9}
------------------------------------

Protein cytotoxicity is assessed using a lactate dehydrogenase (LDH) assay according to the manufacturer\'s instructions by means of a Cytotoxicity Detection Kit^PLUS^ (Roche).

2.10. ELISA for IFN-β {#sec2.10}
---------------------

HEK293T cells are infected with VSV at a MOI of 0.1 for indicated times, in the presence or absence of G4-T. The supernatants are harvested for ELISA (PBL Biomedical Laboratories) with a commercial sandwich kit (TFB), according to the manufacturer\'s instructions.

2.11. Preparation of cell lysates and immunoblots {#sec2.11}
-------------------------------------------------

The cells are harvested and dissolved in 200 μl lysis buffer (pH 7.5 20 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 2.5 mM Sodium pyrophosphate, 1 mM β-Glycerrophosphate, 1 mM Sodium orthovanadate, 1 μg/ml Leupeptin) in the presence of the protease inhibitor cocktail for 30 min at 4 °C and finally disrupted by sonication. After then, the cell suspension is fractionated by centrifugation at 6000*g* for 20 min at 4 °C. Solubilized proteins are harvested, electrophoresed in denaturing polyacrylamide gels, transferred to a polyvinylidene fluoride membrane and reacted with the antibodies indicated. Protein bands are detected with secondary antibody conjugated to horseradish peroxidase (HRP), and actin is used as a loading control.

2.12. Determination of TCID~50~ {#sec2.12}
-------------------------------

Cells are mock-infected or exposed to viruses in mixture supplemented with DMEM. After 90 min the inoculum is replaced with DMEM containing 2% FBS and incubated for 48 h or 72 h (only for HSV-1). Virus titration is performed in cells cultured in 96-well plate at 10^4^ cells/well 24 h prior to the assay to achieve 80% confluency. Ten-fold serial dilutions are prepared for each sample and 100 μl/well of each dilution are added to the cells in quadruplicates. Wells with cytopathic effect are scored as positive for virus growth and log~10~ TCID~50~/ml is determined by the method of Reed and Muench.

2.13. Reed and Muench method {#sec2.13}
----------------------------

Log~10~ 50% end point dilution = log~10~ of dilution showing a mortality next above 50% - (difference of logarithms × logarithm of dilution factor). Generally, the following formula is used to calculate "difference of logarithms" (difference of logarithms is also known as "proportionate distance" or "interpolated value"): Difference of logarithms = \[(mortality at dilution next above 50%)-50%\]/\[(mortality next above 50%)-(mortality next below 50%)\].

2.14. HCV infectivity {#sec2.14}
---------------------

HCV infectivity titers are determined by focus-forming units (FFU) assay. In brief, Huh7.5.1 cells seeded in a 96-well plate are infected with indicated MOI of HCV for different times. The number of FFU is counted automatically by an ImmunoSpot Series 5 UV Analyzer with customized software (CTL Europe GmbH). The viral infectivity titers in FFU/ml are averages from three independent assays.

2.15. siRNA interference {#sec2.15}
------------------------

Cells in T-25 flask grown to 30--40% confluency are transfected with 200 pmol of siRNA (Santa Cruz) by using Lipofectamine™ 2000 (Invitrogen) according to manufacturer\'s protocols.

2.16. Design of shRNA {#sec2.16}
---------------------

Invitrogen BLOCK-iT™ RNAi (<https://rnaidesigner.thermofisher.com>) is used to design siRNAs targeting Gallus GLTSCR2. Based on the siRNA screening results, shRNA-158, siRNA-243, and siRNA-1370 are predicted to have the best suppression effect and are selected to design shRNA. The shRNA sequences targeting Gallus GLTSCR2 are as follows (5′-3′; only the sense strand is shown). shRNA-158: GCG ATT TCC TCG AGG ATG TGA; shRNA-243: GGA TAC GGG CAA TGC TGA GAA; shRNA-1370: GCC TGA AGT ACG TGG AGA AGA. The shRNA expression vector pGPU6/GFP/Neo is selected to be the parental plasmid. All these DNA oligonucleotides are chemically synthesized by Invitrogen.

2.17. Transfection of shRNA plasmids {#sec2.17}
------------------------------------

Cells grown to 60--80% confluency are transfected with plasmid-based shRNA by using Lipofectamine™ 2000 according to manufacturer\'s protocols.

2.18. SPF chicken embryo assay {#sec2.18}
------------------------------

For each inoculation, a mixture of shRNA plasmid (10 μg), Lipofectamine (10 μl), NDV (50 PFU, 50 μl) or AIV (500 PFU, 100 μl) is injected into the allantoic cavity of 9-day chicken eggs. Eggs are incubated for different times, and allantoic fluid is harvested to measure virus titer. All the embryos infected with NDV (50 PFU) or AIV (500 PFU) alive under the experimental condition.

2.19. Hemagglutination (HA) assay {#sec2.19}
---------------------------------

Each allantoic fluid is collected and two-fold serially diluted in sterile saline; each dilution of 50 μl is reacted against an equal volume of 1% of washed red blood cells (RBC) of chicken. The maximum dilution of allantoic fluid that still results in complete agglutination of RBC suspension is recorded as HA unit (HAU). An experiment is performed three times, and the viral infectivity titers in HAU value are averages from two independent assays.

3. Results {#sec3}
==========

3.1. Recombinant protein G4-T folds in an α-helical dimer structure {#sec3.1}
-------------------------------------------------------------------

Previously, we showed that the C-terminal region G4 (amino acids 241--478) of GLTSCR2 participates in optimal VSV replication ([@bib43]). In the current study, His-fusion protein G4-T is produced, in which cell-penetrating peptide Tat (GGSRYGRKKRRQRRR) is conjugated at the C-terminal of G4. Recombinant protein G4-T is purified by Ni-column and eluted with a Tris-HCl buffer containing imidazole at concentrations of 10, 20, 50, or 200 mM. Results show that G4-T is highly soluble in 20 mM imidazole with over 85% purity at a concentration of about 1 mg/ml ([Fig. 1](#fig1){ref-type="fig"} A, lane 5). G4-T is then passed over a Superdex G200 column. This results in the self-association of G4-T into a dimer structure with a molecular mass of 52 kDa in a Tris-HCl buffer ([Fig. 1](#fig1){ref-type="fig"}B). Chemical cross-linking analysis confirms the formation of dimers of G4-T in the presence of 0.05% Glutaraldehyde (GA) (lane 4).Fig. 1Structural analysis of recombinant protein G4-T. ***(A)*** Production and purification of His-fusion G4-T. Lane 1, protein molecular-weight markers in kDa as indicated; lane 2--3, insoluble and soluble fractions of G4-T protein from *E. coli* lysate after sonication and centrifugation; lanes 4--7, G4-T was purified by His-Ni column with imidazole at concentrations of 10, 20, 50, and 200 mM. The fusion proteins were analyzed on 10% SDS-PAGE. ***(B)*** His-fusion G4-T was passed over the Superdex G200 column. The inset picture is 10% SDS-PAGE analysis of the peak protein (lane 1) and marker (lane 2), peak protein treated with 0% (lane 3) or 0.05% GA (lane 4) was analyzed by immunoblotting with antibody to His. ***(C)*** CD spectra of the purified G4-T in PBS solution with 0%, 25%, and 50% TFE. A typical α-helix secondary structure is showed with double minima at 208 and 222 nm. ***(D)*** Thermal denaturation of G4-T at wavelength of 222 nm.Fig. 1

Circular dichroism (CD) spectrometry is performed to study the secondary structural changes in PBS with and without 2,2,2-trifluoroethanol (TFE). TFE is widely used in conformational studies because it promotes intramolecular hydrogen bonds in spite of intermolecular interactions with water molecules, and thus, lowers the polarity of the solution ([@bib7]). Results show that G4-T protein exhibits a tendency to form a α-helical secondary structure in a PBS buffer solution. The tendency to form α-helical secondary structure for G4-T protein in the presence of 25% and 50% TFE is more obvious than that in the absence of TFE ([Fig. 1](#fig1){ref-type="fig"}C). This result indicates that there is no effect of polarity on protein conformation when G4-T is transferred from water to membrane interfaces. The α-helix structure, however, disappears when the temperature exceeds 65 °C ([Fig. 1](#fig1){ref-type="fig"}D).

3.2. G4-T promotes efficient proliferation of viruses belonging to 6 families {#sec3.2}
-----------------------------------------------------------------------------

To explore if G4-T protein promotes efficient proliferation of viruses, cells infected with Newcastle disease virus (NDV) and HSV-1 are treated with G4-T at concentrations of 10, 20, and 30 μg/ml. As shown in [Fig. 2](#fig2){ref-type="fig"} A, G4-T protein increases the expression level of NDV-N and HSV-ICP8 mRNA; the level being dependent on the dose. 4--6 fold increase in mRNA level is observed when treated with G4-T at the concentration of 20 μg/ml. To investigate whether G4-T protein has a toxic effect on cells, HEp-2 and Vero cells are cultured in a medium containing different concentrations (0, 10, 20, and 40 μg/ml) of G4-T protein for 24 h. Cell viability is then assessed using LDH assay. No significant difference is observed between untreated and G4-T treated cells ([Fig. 2](#fig2){ref-type="fig"}B). The cell lines are then treated with G4-T at 20 μg/ml and TCID~50~ is measured following virus infections. As shown in [Fig. 2](#fig2){ref-type="fig"}C, G4-T increases virus yield in TCID~50~ by 16, 32, 13, 208, 13, 10, 62, and 58 folds, as compared with cells infected in a controlled manner with EV-A71, AIV, CDV, clinically new isolated NDV, PEDV, IBV, VSV, and HSV-1, respectively.Fig. 2G4-T promoted the proliferation of viruses and suppressed the production and activity of IFN-β. (***A)*** HEp-2 cells in T-25 flask were infected with NDV or HSV-1 of 10 PFU in the presence of G4-T at different concentrations of 0, 10, 20, and 30 μg/ml, NDV-N and HSV-ICP8 mRNA were quantified by RT-PCR at 48 h post-infection (h.p.i.). The values were normalized to the internal control (glyceraldehyde-3-phosphate dehydrogenase \[GAPDH\]) and expressed as relative fold changes over the control. These experiments were performed two times with three replicates in each experiment. Values represent means and standard deviations (SD). Statistical analysis was evaluated by one-way analysis of variance with Dunnett\'s multiple-comparison test. \**p* \< 0.05, \*\**p* \< 0.01 compared with control group. ***(B)*** Effects of G4-T on cell viability of cultured HEp-2 and Vero cells. Cells were treated with various concentrations of G4-T for 24 h, and cell viability was determined by LDH assay. These experiments were performed two times with three replicates in each experiment. Values represent means and SD. Statistical analysis was evaluated by one-way analysis of variance with Dunnett\'s multiple-comparison test. \*\**p* \< 0.01, \*\*\**p* \< 0.001 compared with control group. ***(C)*** Cells were infected with viruses at 10 TCID~50~ or 1 TCID~50~ (only for EV-A71) in the presence of PBS or G4-T (20 μg/ml) for 48 h or 72 h (only for HSV-1), virus titer was presented as log~10~ TCID~50~/ml. These experiments were performed two times with three replicates in each experiment. Values represent means and SD. ***(D)*** HEK293T cells in T-25 flask were infected with VSV at a MOI of 0.1 for 12 h, in the presence of PBS or G4-T (20 μg/ml). Total RNA was isolated and used for quantification of IFN-β, PKR, and ISG56 mRNA levels by RT-PCR. These experiments were performed two times with three replicates in each experiment. Statistical analysis was evaluated by student\'s *t*-test. \*\**p* \< 0.01, \*\*\**p* \< 0.001 compared with PBS-treated group. ***(E)*** HEK293T cells in 24-well plate were infected with VSV at a MOI of 0.1 for indicated times, in the presence of PBS or G4-T (20 μg/ml). The supernatants from cells were harvested and analyzed for IFN-β production by ELISA. These experiments were performed two times with three replicates in each experiment. Statistical analysis was evaluated by student\'s *t*-test. \*\*\**p* \< 0.001 compared with PBS-treated group. ***(F)*** HEK293T cells were infected with VSV at a MOI of 0.1 in the presence of G4-T (20 μg/ml) (lanes 2--3) and commercially available IFN-β (10 ng/ml) (lanes 3--4), the virus yields were determined 48 h later, as log~10~ TCID~50~/ml. These experiments were performed two times with three replicates in each experiment. Values represent means and SD. Statistical analysis was evaluated by one-way analysis of variance with Dunnett\'s multiple-comparison test. \*\**p* \< 0.01 compared with untreated group. Under the same experimental condition, electrophoretically separated proteins were analyzed by immunoblotting with specific antibody to viral protein VSV-G, with actin as a control (right).Fig. 2

3.3. G4-T suppresses type I IFN antiviral response {#sec3.3}
--------------------------------------------------

To examine if G4-T promotes proliferation of viruses by abrogating the expression of type I IFN, we measure the mRNA levels of IFN-β, PKR, and ISG56. As shown in [Fig. 2](#fig2){ref-type="fig"}D, there is a 2--3 fold reduction in mRNA level when treated with G4-T protein at 20 μg/ml. In addition, HEK293T cells treated with G4-T protein and infected with VSV for 9, 12, and 24 h, show significantly reduced levels of IFN-β secretion ([Fig. 2](#fig2){ref-type="fig"}E). It is also observed that G4-T increases VSV yield in TCID~50~ by 30 folds, and increases the expression level of VSV-G ([Fig. 2](#fig2){ref-type="fig"}F, lane 2). Commercially available IFN-β at a concentration of 10 ng/ml decreases the virus titer and expression of VSV-G enhanced by G4-T (lane 3). These results indicate that G4-T protein sensitizes host cells to the virus by suppressing their antiviral response.

3.4. G4-T promotes fast and efficient proliferation of HCV {#sec3.4}
----------------------------------------------------------

To explore if G4-T protein promotes viral proliferation, three well-established HCV infectivity assays are performed. Our results show that G4-T at 20 μg/ml increases HCV yield in FFU by 10--50 folds over a broad MOI range from 0.0001 to 0.1. However, G4-T does not play a role at MOI of 1 ([Fig. 3](#fig3){ref-type="fig"} A). We also explored the effect of G4-T on the expression of viral mRNA throughout the entire infection course. As shown in [Fig. 3](#fig3){ref-type="fig"}B, G4-T significantly enhances the intracellular level of HCV-NS5A mRNA at 8, 12, and 24 h post-infection (h.p.i.). We also find that the expression levels of HCV-NS5A mRNA present in a similar manner in the presence and absence of G4-T at 12 h.p.i. and 24 h.p.i., respectively. A similar behavior is observed in the presence of G4-T at 24 h.p.i. and in the absence of G4-T at 48 h.p.i. ([Fig. 3](#fig3){ref-type="fig"}B). The results shown in [Fig. 3](#fig3){ref-type="fig"}A and B indicate that G4-T promotes efficient replication of HCV in a virus titer in a time-dependent manner. Furthermore, Huh7.5.1 cells are transfected with the linear Jc1-Luc HCV plasmid, followed by treatment with G4-T protein; cell lysates are subjected to luciferase assay. The result shows that G4-T improves *in vitro* transcription of Jc1-Luc HCV ([Fig. 3](#fig3){ref-type="fig"}C). Finally, the HCV genotype 1b replicon-containing cell line (2−3+) is seeded in the presence of G4-T. We observe that G4-T up-regulates the expression of HCV-core ([Fig. 3](#fig3){ref-type="fig"}D). Based on the above results, we can conclude that G4-T treatment is associated with a more efficient replication of HCV.Fig. 3G4-T promoted fast and efficient replication of HCV. ***(A)*** Huh7.5.1 cells were exposed to HCV at a MOI of 0.0001, 0.001, 0.01, 0.1, 1.0, in the presence of G4-T (20 μg/ml), IFN-β (10 ng/ml), or PBS for 48 h. Virus titer was presented as log~10~ FFU/ml. Statistical analysis was evaluated by two-way analysis of variance with Dunnett\'s multiple-comparison test. ***(B)*** Huh7.5.1 cells were exposed to HCV at a MOI of 0.1 for indicated times, in the presence of G4-T, IFN-β, or PBS. Total RNA was isolated; HCV-NS5A mRNA was quantified by RT-PCR, and assessed as described in [Fig. 2](#fig2){ref-type="fig"}A. Statistical analysis was evaluated by two-way analysis of variance with Dunnett\'s multiple-comparison test. ***(C)*** Huh7.5.1 cells were transfected with the linear Jc1-Luc HCV plasmid for 48 h, in the presence of G4-T, IFN-β, or PBS. The cells were lysed and assayed with luciferase assay system in a Modulus Microplate Luminometer. We typically obtain counts ranging from 10,000--900,000, whereas the background signal from bald virus infected sample is usually below 100. Statistical analysis was evaluated by one-way analysis of variance with Dunnett\'s multiple-comparison test. \**p* \< 0.05, \*\**p* \< 0.01 compared with PBS-treated group. ***(D)*** The HCV genotype 1b replicon-containing cell line (2−3+) was seeded as triplicates in 48-well plate the day before treated for 48 h, in the presence of G4-T, IFN-β, or PBS. Total RNA was isolated; HCV-NS5A mRNA was quantified by RT-PCR, and assessed as described in Fig. 3B. Statistical analysis was evaluated by one-way analysis of variance with Dunnett\'s multiple-comparison test. The cells were also harvested and immunoblotted with antibody to viral protein HCV-core, with actin as a control. All the experiments were performed at least two times with three replicates in each experiment. Values represent means and SD. \**p* \< 0.05, \*\**p* \< 0.01 compared with PBS-treated group.Fig. 3

3.5. G4-T promotes viral proliferation of GFP-NDV {#sec3.5}
-------------------------------------------------

To quantify the effect of G4-T treatment on the efficiency with which virus infection induces syncytium formation, cells are infected with a recombinant NDV expressing the green fluorescent protein (GFP) and cultured for 24, 48, and 60 h. The syncytiums number is then analyzed by fluorescence microscopy. As shown in [Fig. 4](#fig4){ref-type="fig"} A--C, GFP-NDV produces a larger number of syncytiums in cells treated with G4-T at 20 μg/ml as compared to those not treated with G4-T. These results demonstrate that the G4-T protein plays a significant role in promoting the spreading of the virus. In addition, G4-T treatment for 60 h does not induce syncytium formation ([Fig. 4](#fig4){ref-type="fig"}D). Viral replication is further confirmed by examining the expression of NDV-P. As shown in [Fig. 4](#fig4){ref-type="fig"}E, G4-T significantly promotes viral replication at 24 and 48 h.p.i., but is ineffective at 60 h.p.i. These results indicate that G4-T protein enhances the spreading and replication of GFP-NDV in a time-dependent manner.Fig. 4G4-T affected syncytium number and viral replication of GFP-NDV. DF-1 cells in 48-well plate were exposed to GFP-NDV of 10 TCID~50~ for 24 h ***(A)*,** 48 h ***(B)***, and 60 h ***(C)***, in the presence of PBS or G4-T (20 μg/ml). The syncytiums were imaged using a DP73 camera by fluorescence microscopy on an Olympus IX73 microscope 25 (magnification of 100×) (panels a--b), and were assessed under light microscopy (panels c--d). One image is representative of three. ***(D)*** DF-1 cells were treated with G4-T (20 μg/ml) for 60 h, then were imaged by fluorescence microscopy (panel a) and light microscopy (panel b). ***(E)*** DF-1 cells in T-25 flask were infected with GFP-NDV of 100 TCID~50~ in the presence of PBS or G4-T (20 μg/ml). At 24, 48, and 60 h.p.i., cells were harvested and electrophoretically separated proteins were analyzed by immunoblotting with antibody to viral protein NDV-P, with actin as a control.Fig. 4

3.6. GLTSCR2 knockdown reduces viral infection in mammalian and chicken cells {#sec3.6}
-----------------------------------------------------------------------------

Our previous study showed that GLTSCR2 knockdown results in a reduced production of viral particles of VSV, NDV, and IBV by 60, 120, and 20 folds, respectively ([@bib43]). In the present study, commercially available small interfering RNA (siRNA), which targets GLTSCR2 gene, efficiently suppresses mRNA levels of viral proteins of NDV-N ([Fig. 5](#fig5){ref-type="fig"} A), IBV-N ([Fig. 5](#fig5){ref-type="fig"}B), and HSV-ICP8 ([Fig. 5](#fig5){ref-type="fig"}C) in HEp-2 cells. GLTSCR2-specific siRNA is also able to suppress the expression of NDV-P, CDV-N, and VSV-G in HeLa, Vero, and HEK293T cells, respectively ([Fig. 5](#fig5){ref-type="fig"}D). This result indicates that GLTSCR2 knockdown inhibits the replication of multiple viruses.Fig. 5Effect of GLTSCR2 knockdown on viral replications in cells. HEp-2 cells in T-25 flask were transfected with negative siRNA or siRNA targeting GLTSCR2 for 72 h, subsequently were infected with NDV (strain Lasota), IBV, and HSV-1 of 10 PFU for indicated times. Total RNA was isolated; NDV-N ***(A)***, IBV-N ***(B)***, and HSV- ICP8 ***(C)*** mRNA were quantified by RT-PCR, and assessed as described in [Fig. 2](#fig2){ref-type="fig"}A. These experiments were performed two times with three replicates in each experiment. Values represent means and SD. Statistical analysis was evaluated by student\'s *t*-test. \**p* \< 0.05 compared with negative siRNA-treated group. ***(D)*** HeLa, Vero, and HEK293T cells in T-25 flask were transfected with negative siRNA or siRNA (200 pmol each) targeting GLTSCR2 for 72 h, subsequently were infected with NDV (strain Lasota), CDV, and VSV of 10 PFU for 48 h. Electrophoretically separated proteins were immunoblotted with indicated antibodies, with actin as a control. ***(E)*** The shRNA-expressing plasmids (5 μg each) were transfected into DF-1 cells in 6-well plate for 96 h, and then infected with GFP-NDV (strain NA-1) of 50 TCID~50~. At 36 and 48 h.p.i., DF-1 cells were harvested and virus titer was presented as log~10~ TCID~50~/ml. These experiments were performed two times with three replicates in each experiment. Values represent means and SD. Statistical analysis was evaluated by one-way analysis of variance with Dunnett\'s multiple-comparison test. \*\**p* \< 0.01, \*\*\**p* \< 0.001 compared with negative shRNA-treated group. Efficiency of knockdown was analyzed by immunoblotting with specific antibody to GLTSCR2, with actin as a control (bottom).Fig. 5

Newcastle disease is one of the most important avian diseases in poultry. Virulent variant strains of NDV are sporadically isolated from vaccinated chickens, wild birds, and even swine ([@bib54]). In the present research effort, chicken embryo fibroblast DF-1 cells are transfected with recombinant plasmids carrying shRNA that are designed to target GLTSCR2, i.e., shRNA-158, shRNA-243, and shRNA-1370. As shown in [Fig. 5](#fig5){ref-type="fig"}E, shRNA-243 and shRNA-1370 reduces virus titer in TCID~50~ by 100 folds at 36 h.p.i., and by 250 and 1000 folds at 48 h.p.i., respectively. shRNA-158 does not significantly affect the virus titer. It can be concluded that GLTSCR2 knockdown reduces viral infection in mammalian and chicken cells. These results also indicate that shRNA-1370 exhibits stronger inhibition characteristics as compared with shRNA-243 treatment.

3.7. GLTSCR2-specific shRNAs reduce GFP-NDV infection in chicken embryos {#sec3.7}
------------------------------------------------------------------------

We further examined the ability of shRNA expression plasmid of shRNA-1370, which targeting Gallus GLTSCR2 (nucleic acid 1370--1390), to reduce GFP-NDV proliferation in chicken embryos. This is widely used *in vivo* model of viral infection, especially for NDV ([@bib55]) and influenza virus ([@bib16]). GFP-NDV and shRNA-1370 are injected with lipofectamine of a lipid-based carrier into the allantoic cavity of 9-day-old specific pathogen-free (SPF) chicken embryos. Allantoic fluids are harvested 36, 48, 60, 72, 84, and 96 h post infection to measure virus titers in DF-1 cells. We detect that treatment with 2.5 μg of shRNA-1370 does not affect the virus titer, while 5 μg of shRNA-1370 has a slight effect on it (not shown here). 10 μg of GLTSCR-specific shRNA provides the optimal inhibitory activity and is administered in subsequent experiments.

Our results demonstrate that treatment with shRNA-1370 at 24 h prior to ([Fig. 6](#fig6){ref-type="fig"} ) or simultaneous ([Fig. 7](#fig7){ref-type="fig"} ) infection with GFP-NDV results in the reduced production of viral particles. Injection of chicken embryo with the GLTSCR2-specific shRNA-1370 at 24 h prior to infection with NDV decreases the virus titer in TCID~50~ by 4, 3, 7, 6, 13, and 61 folds ([Fig. 6](#fig6){ref-type="fig"}); while a simultaneous shRNA-1370 treatment with NDV infection reduces TCID~50~ by 6, 4, 20, 29, 17, and 66 folds, at 36, 48, 60, 72, 84, and 96 h.p.i., respectively ([Fig. 7](#fig7){ref-type="fig"}). In summary, shRNA-1370 effectively reduces NDV replication in chicken embryos.Fig. 6Pre-treatment of GLTSCR2-specific shRNA-1370 reduced GFP-NDV infection in chicken embryos. ***(A)*** Each shRNA (shRNA-1370, shRNA-Neg) (10 μg each) was injected into the allantoic cavity of a 9-day-old SPF chicken egg used 24 h prior to GFP-NDV inoculation (50 PFU). The eggs were incubated at 37 °C for 36, 48, 60, 72, 84, and 96 h with observation every 6 h. The eggs were stored immediately at 4 °C every 12 h, and all eggs were harvested and analyzed at the same time. The virus titer of allantoic fluid was determined as log~10~ TCID~50~/ml by fluorescence microscopy in DF-1 cells. These experiments were performed two times with three replicates in each experiment. Values represent means and SD. Statistical analysis was evaluated by two-way analysis of variance with Bonferroni's multiple comparisons test. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 compared with negative shRNA-treated eggs. ***(B)*** Specific fluorescence in DF-1 cells infected with GFP-NDV was imaged by fluorescence microscopy (magnification of 100×), one image is representative of three. The description (1:10^4^, 1:10^5^, 1:10^6^, and 1:10^7^) indicated the dilution of NDV-infected allantoic fluid used for inoculation of cells.Fig. 6Fig. 7Co-treatment of shRNA-1370 reduced GFP-NDV infection in chicken embryos. ***(A)*** Each shRNA (shRNA-1370, shRNA-Neg) (10 μg each) was injected into the allantoic cavity of a 9-day-old SPF chicken egg simultaneously with GFP-NDV inoculation (50 PFU). The egg were incubated for 36, 48, 60, 72, 84, and 96 h and analyzed at the same time. The virus titer in allantoic fluid was determined as log~10~ TCID~50~/ml by fluorescence microscopy in DF-1 cells. These experiments were performed two times with three replicates in each experiment. Values represent means and SD. Statistical analysis was evaluated by two-way analysis of variance with Bonferroni's multiple comparisons test. \*\**p* \< 0.01, \*\*\**p* \< 0.001 compared with negative shRNA-treated eggs. ***(B)*** Specific fluorescence in DF-1 cells infected with GFP-NDV was imaged by fluorescence microscopy (magnification of 100×), one image is representative of three. The description (1:10^5^ and 1:10^6^) indicated the dilution of NDV-infected allantoic fluid used for inoculation of cells.Fig. 7

3.8. GLTSCR2-specific shRNA-1370 reduces AIV infection in chicken embryos {#sec3.8}
-------------------------------------------------------------------------

To study the effect of shRNA-1370 on AIV infection in SPF chicken embryos, virus titers from allantoic fluids of chicken embryos are measured by HA assay. As shown as in [Fig. 8](#fig8){ref-type="fig"} A, shRNA-1370 treatment at 24 h prior to infection with AIV reduces HAU value by 3 folds at 96 h.p.i. However, it does not significantly affect the virus titer at 36, 48, and 72 h.p.i. In contrast, simultaneous shRNA-1370 treatment with AIV infection reduces HAU value by 2, 4, and 3 folds at 48, 72, and 96 h.p.i. Our results demonstrate that shRNA-1370 effectively interferes with AIV proliferation in chicken embryos.Fig. 8GLTSCR2-specific shRNA-1370 reduced AIV infection in chicken embryos. The shRNA-1370 or shRNA-Neg (10 μg each) was injected into the allantoic cavity of a 9- day-old SPF chicken eggs used 24 h prior to ***(A)*** or simultaneously ***(B)*** infection with AIV (500 PFU). After shRNA injection and virus inoculation, the eggs were incubated for 36, 48, 72, and 96 h. Virus titers in allantoic fluids were determined as log~2~ HAU/50 μl. These experiments were performed two times with three replicates in each experiment. Values represent means and SD. Statistical analysis was evaluated by two-way analysis of variance with Bonferroni's multiple comparisons test. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 compared with negative shRNA-treated eggs.Fig. 8

4. Discussion {#sec4}
=============

Virus cultivation still remains a major challenge in the field of general virology because viral propagation is difficult and time consuming, especially for the novel clinically isolated and re-emerging viruses. Several studies, including the ones conducted by [@bib2] and [@bib18], have shown that viral proteins may counteract IFN antiviral response to facilitate their replication. The permanent cell lines stably expressing these viral proteins have been established for optimal in replication of viruses including paramyxovirus ([@bib53]) and herpesviruses ([@bib13], [@bib28]). It is thus inferred that if the accumulation of negative regulators of type I IFN is increased in cells, they are more susceptible to virus infection than the parent control cells. In the present study, we address the key challenges that remain towards developing more efficient virus cultivation, and establish a simple approach that substantially inoculate viruses by directly adding recombinant protein G4-T in a culture medium of mammalian cells. G4-T protein, a negative regulator of type I IFN, can promote efficient proliferation of at least 9 laboratory adapted and clinically isolated viruses, including the families, *Rhabdoviridae* (VSV), *Orthomyxoviridae* (AIV), *Paramyxoviridae* (NDV, CDV), *Coronaviridae* (PEDV, IBV), *Picornaviridae* (EV-A71), *Flaviviridae* (HCV), and *Herpesviridae* (HSV-1). This work provides a feasible countermeasure for optimizing viral replication for both enveloped and non-enveloped DNA and RNA viruses. G4-T protein is expected to treat viruses in clinical samples that are fastidious and difficult to cultivate, and vaccine strains from wild-type isolates. Our study highlights the potential of the cellular protein GLTSCR2 to be a valuable target for the development of broad-spectrum class of antivirals.

Over the past 10 years numerous applications have successfully used the RNA interference (RNAi) technology. It is based on the fact that small interfering RNA (siRNA) molecules or short hairpin RNAs (shRNAs) target viral and cellular mRNA, which results in the degradation and suppression of specific gene expressions ([@bib3], [@bib11]). The development of the plasmid-based technology to produce shRNA, driven by the U6 promoter, has made long term and inducible gene silencing possible ([@bib38]). A number of studies have demonstrated that RNAi-mediated gene suppression of pathogenic viruses to be highly effective against many human and animal viruses both *in vitro* and *in vivo* ([@bib5], [@bib12], [@bib19], [@bib20], [@bib36]). The siRNA- and shRNA-mediated knockdown can inhibit viral replication of NDV and AIV in chicken cells and embryos. The plasmid-based shRNA that targets matrix protein M of NDV ([@bib52]) and nucleocapsid protein NP of AIV ([@bib1]) leads to a yield reduction of 80 and 400 folds in cells, respectively. Furthermore, shRNA targets NP of NDV that is delivered into the chicken embryos and reduces HA value by 10 folds in virus titer ([@bib55]), while siRNA targets NP of AIV and reduces HAU value by 8 folds ([@bib16]).

In this study, GLTSCR2-specific shRNA-1370 is evaluated for antiviral activity against NDV and AIV by means of virus titration in chicken cells and embryos. Our results show that plasmid-based shRNA-1370 induces up to 1000-fold decrease in the infective titer in cells infected with NDV ([Fig. 5](#fig5){ref-type="fig"}). In our chicken embryo experiments, NDV of 50 PFU in 50 μl has been selected to inject into the allantoic cavity of 9-day chicken eggs. Infected eggs are stored immediately at 4 °C for 12 h, and all eggs are harvested and analyzed simultaneously for consistency. Under this experimental condition, NDV titer reaches the peak at 96 h.p.i. As shown in [Fig. 6](#fig6){ref-type="fig"}, [Fig. 7](#fig7){ref-type="fig"}, [Fig. 8](#fig8){ref-type="fig"}, application of shRNA-1370 substantially reduces viral replication of NDV and AIV in chicken embryo fibroblasts. There are two time milestones that are noteworthy. At 96 h.p.i, the case with a shRNA-1370 treatment simultaneously or 24 h prior to infection with NDV substantially reduces the virus titer in TCID~50~ by over 60 folds, and in HAU value by 3 folds for AIV. It is suggested that the shRNA-1370 treatment has substantial effect on viral replication. The impact is stronger with increasing treatment time. At 72 h.p.i, beyond our expectation, a simultaneous shRNA-1370 treatment with NDV infection reduces the virus titer in TCID~50~ by 29 folds, and in HAU value by 4 folds for AIV. The antiviral effect at 72 h.p.i. is more prominent than that at 48, 60, and 84 h.p.i. This interesting issue remains to be addressed. There is limited literature describing shRNA plasmid-based platforms that target cellular proteins utilized by viruses for *in vivo* proliferation. Our study provides a model for the screening and identification of cell-based antivirals. This work also provides a new idea for the design of an intervention strategy against multiple viruses by targeting negative feedback regulators of type I IFN.

Colon and esophageal cancers in humans that harbor low levels of GLTSCR2 show a better 5-year survival rate than patients whose cancers have high GLTSCR2 levels ([@bib34]). Therefore, small molecule inhibitors that are designed based on GLTSCR2-specific shRNA are expected to act as broad therapy against viral infection, without cytotoxicity and side-effects on host cells. We are currently investigating structure-based design of small molecule antagonist.
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